Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: January 23, 2013
Event: Announcement of results of operations for the fourth quarter and full year 2012.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notice that these results were announced and refers to a press release (Exhibit 99.1) for the detailed data.
The company utilizes non-GAAP financial measures, including net earnings and diluted earnings per share excluding specified items, to evaluate ongoing business performance.
Material Changes and Adjustments
While specific comparative figures are absent from this text, the filing details the specific items excluded from non-GAAP measures to adjust for unusual or unpredictable factors. These include:
- Acquisition-related costs
- Asset impairments
- Losses on extinguishment of debt
- Costs related to the separation of Abbott's research-based pharmaceuticals business
- Litigation reserves
- Acquired in-process research and development
- Tax audit settlements
- Restructuring and integration costs
- Cost reduction initiatives
- Effect of the change in the calendar year-end for international operations
Guidance, Outlook, and Management Commentary
Management states that the presentation of non-GAAP measures provides useful information for investors to better evaluate ongoing business performance and is used internally to monitor business performance. However, management cautions that these measures should be considered in addition to, and not as a substitute for, GAAP financial measures. No specific forward-looking guidance or outlook figures are contained within this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 23, 2013) for specific revenue, earnings, and cash flow figures.
- Verify the reconciliation between GAAP and non-GAAP financial measures to understand the impact of the excluded items listed above.
- Assess the magnitude of costs related to the separation of the research-based pharmaceuticals business.
- Confirm the impact of the calendar year-end change for international operations on the reported results.